LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

Search

MiNK Therapeutics

Uždarymo kaina

10.95 -3.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.87

Max

11.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-12B

-12B

Pelnas, tenkantis vienai akcijai

-0.56

Darbuotojai

23

EBITDA

287K

-2.6M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+212.22% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.4M

58M

Ankstesnė atidarymo kaina

14.3

Ankstesnė uždarymo kaina

10.95

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

MiNK Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 23:58; UTC

Uždarbis

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026-05-07 22:57; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026-05-07 23:52; UTC

Uždarbis

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026-05-07 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-07 23:39; UTC

Rinkos pokalbiai

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026-05-07 23:28; UTC

Rinkos pokalbiai

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026-05-07 23:11; UTC

Uždarbis

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026-05-07 23:06; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026-05-07 23:05; UTC

Uždarbis

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026-05-07 23:04; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026-05-07 23:02; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026-05-07 23:00; UTC

Rinkos pokalbiai

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026-05-07 22:42; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026-05-07 22:33; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:32; UTC

Uždarbis

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie: 68% of FY Income From International >MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026-05-07 22:29; UTC

Uždarbis

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026-05-07 22:26; UTC

Uždarbis

Macquarie to End Share Buyback Extended in November>MQG.AU

2026-05-07 22:25; UTC

Uždarbis

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Akcijų palyginimas

Kainos pokytis

MiNK Therapeutics Prognozė

Kainos tikslas

By TipRanks

212.22% į viršų

12 mėnesių prognozė

Vidutinis 35 USD  212.22%

Aukščiausias 35 USD

Žemiausias 35 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MiNK Therapeutics kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

7.81 / 8.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

help-icon Live chat